Cargando…

Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province

OBJECTIVES: Patients with Hepatitis C Virus infection are at high risk of getting hepatitis A virus. Hepatitis A virus is an important widespread virus that usually causes more severe medical consequences in patients with chronic liver disease. The purpose of this study was to evaluate prevalence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoaei, Parisa, Zeidabadinejad, Laleh, Hassannejad, Razieh, Ataei, Behrooz, Yaran, Majid, Kassaian, Nazila, Nokhodian, Zary, Foroughifar, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399306/
https://www.ncbi.nlm.nih.gov/pubmed/22826750
_version_ 1782238388208795648
author Shoaei, Parisa
Zeidabadinejad, Laleh
Hassannejad, Razieh
Ataei, Behrooz
Yaran, Majid
Kassaian, Nazila
Nokhodian, Zary
Foroughifar, Maryam
author_facet Shoaei, Parisa
Zeidabadinejad, Laleh
Hassannejad, Razieh
Ataei, Behrooz
Yaran, Majid
Kassaian, Nazila
Nokhodian, Zary
Foroughifar, Maryam
author_sort Shoaei, Parisa
collection PubMed
description OBJECTIVES: Patients with Hepatitis C Virus infection are at high risk of getting hepatitis A virus. Hepatitis A virus is an important widespread virus that usually causes more severe medical consequences in patients with chronic liver disease. The purpose of this study was to evaluate prevalence of Hepatitis A Virus antibody in patients with chronic HCV in Isfahan province, Iran. METHODS: A cross-sectional study was carried out on 117 patients with chronic hepatitis C virus from spring 2010 to spring 2011. Subject's characteristics such as age, gender, education, genotype of HCV infection and history of intravenous drug use were collected by questionnaire and studied. Statistical analysis was done by SPSS software (version 19.0. 2010, SPSS) using Chi-square test, Fisher Exact tests and Cochran-Armitage trend test. RESULTS: The mean age of the subjects was 33.18 ± 10.97 years. The seroprevalence of HAV was 94.9% in patients with chronic HCV. The prevalence of anti-HAV increased nearly as age increased. But, there was no statistically significant difference in HAV positive rate according to the age groups (P = 0.242) and other patient's characteristics. CONCLUSIONS: According to the high HAV immunity in our study and less severe form of HAV infection, vaccination was not required in these patients. However, hepatitis A vaccination program should be performed in HAV seronegative patients with HCV to produce an adequate immune response.
format Online
Article
Text
id pubmed-3399306
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-33993062012-07-23 Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province Shoaei, Parisa Zeidabadinejad, Laleh Hassannejad, Razieh Ataei, Behrooz Yaran, Majid Kassaian, Nazila Nokhodian, Zary Foroughifar, Maryam Int J Prev Med Original Article OBJECTIVES: Patients with Hepatitis C Virus infection are at high risk of getting hepatitis A virus. Hepatitis A virus is an important widespread virus that usually causes more severe medical consequences in patients with chronic liver disease. The purpose of this study was to evaluate prevalence of Hepatitis A Virus antibody in patients with chronic HCV in Isfahan province, Iran. METHODS: A cross-sectional study was carried out on 117 patients with chronic hepatitis C virus from spring 2010 to spring 2011. Subject's characteristics such as age, gender, education, genotype of HCV infection and history of intravenous drug use were collected by questionnaire and studied. Statistical analysis was done by SPSS software (version 19.0. 2010, SPSS) using Chi-square test, Fisher Exact tests and Cochran-Armitage trend test. RESULTS: The mean age of the subjects was 33.18 ± 10.97 years. The seroprevalence of HAV was 94.9% in patients with chronic HCV. The prevalence of anti-HAV increased nearly as age increased. But, there was no statistically significant difference in HAV positive rate according to the age groups (P = 0.242) and other patient's characteristics. CONCLUSIONS: According to the high HAV immunity in our study and less severe form of HAV infection, vaccination was not required in these patients. However, hepatitis A vaccination program should be performed in HAV seronegative patients with HCV to produce an adequate immune response. Medknow Publications & Media Pvt Ltd 2012-03 /pmc/articles/PMC3399306/ /pubmed/22826750 Text en Copyright: © International Journal of Preventive Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shoaei, Parisa
Zeidabadinejad, Laleh
Hassannejad, Razieh
Ataei, Behrooz
Yaran, Majid
Kassaian, Nazila
Nokhodian, Zary
Foroughifar, Maryam
Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
title Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
title_full Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
title_fullStr Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
title_full_unstemmed Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
title_short Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
title_sort seroprevalence of hepatitis a in patients with chronic hepatitis c in isfahan province
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399306/
https://www.ncbi.nlm.nih.gov/pubmed/22826750
work_keys_str_mv AT shoaeiparisa seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince
AT zeidabadinejadlaleh seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince
AT hassannejadrazieh seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince
AT ataeibehrooz seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince
AT yaranmajid seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince
AT kassaiannazila seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince
AT nokhodianzary seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince
AT foroughifarmaryam seroprevalenceofhepatitisainpatientswithchronichepatitiscinisfahanprovince